Costs per recurrence-free life-monthCosts per recurrence-free survivorIpilimumabMelanomaNivolumabNumber needed to treatObservationIntroduction Nivolumab has been approved in patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. ...
This benefit does come at the cost of an increased severe immune toxic effects risk, a factor that was limiting in prior studies.1,2 In contrast, we observed that both N and N+I were generally well tolerated. Patients did not experience any delays to surgery, and severe immune-related ...
All-cause and RCC-related healthcare costs (unadjusted and adjusted) were assessed per patient per month (PPPM) at 6-month intervals post-treatment initiation (index date) up to 24months, and differences between the NIVO+IPI and PEM+AXI cohorts were compared.#Of 325 patients with aRCC, ...
The primary endpoint is relapse-free survival (RFS), and the secondary endpoints are disease-free survival, overall survival, adverse events, and incremental cost-effectiveness ratio. After the confirmation of patient eligibility including pathological diagnosis, patients will be randomized (1:1:1) to...
Given the substantial risk of toxicity and the cost of NIVO + IPI, this point requires future investigation. 5. Conclusions The present study raises the question of an age limit for the use of NIVO + IPI. Part of the answer depends on ethical and economic considerations, and there is thus...
Nivolumab concentration is stable over a three-month period when plasma is stored at −80 °C [34]. All plasma samples were analyzed within the month after blood collection. 4.4. PD-L1 Expression Analysis Tumor PD-L1 protein expression was evaluated retrospectively in pretreatment (archival or...
Blood cell count is an easy-to-obtain, repeatable, and cost-effective index to represent the status of host immune inflammation. In the present study, we assessed the prognostic impact of seven immune indexes based on immune inflammation in patients with NSCLC treated with second-line or single...